EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study

Ali Kapan iD, Othmar Moser iD, Richard Felsinger iD, Thomas Waldhoer iD, Sandra Haider iD

Diabetes, Obesity and Metabolism · 2025-09 · 27 (9) · 5008-5018

DOI: 10.1111/dom.16548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 24.06.2025. Verfasst von Ali Kapan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Public Health, Department of Social and Preventive Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Obesity, Incretins, Taste Perception, Overweight. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This cross‐sectional study examined associations between self‐reported taste perception changes and appetite‐related outcomes in individuals with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RAS) or dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RAS in real‐world conditions. Materials and Methods Four hundred and eleven adults on Wegovy® ( n = 217), Ozempic® ( n = 148) and Mounjaro® ( n = 46) completed an online survey assessing sociodemographic, anthropometric and sensory changes and appetite‐related outcomes. Multivariable logistic regression was used to assess associations between taste changes and satiety, appetite and craving.

Results

Participants (69.6% female; median age 39 [interquartile range, IQR 33–47]) had baseline body mass index ( BMI) of 35.6 (Wegovy®), 34.7 (Ozempic®) and 36.2 kg/m 2 (Mounjaro®). Adjusted models for baseline BMI , treatment duration, dose, age and sex showed significant reductions in BMI of 17.6% (95% CI : 15.7–19.5) for Wegovy®, 17.4% (15.0–19.8) for Ozempic® and 15.5% (8.8–22.2) for Mounjaro®. Reduced appetite was reported by 58.4% of participants (Wegovy®: 54.4%, Ozempic®: 62.1%, Mounjaro®: 56.5%) and increased satiety by 63.5% (Wegovy®: 66.8%, Ozempic®: 58.8%, Mounjaro®: 63.1%). Additionally, 21.3% reported increased sweet taste perception and 22.6% reported increased salty taste perception. Independent of the type of therapy, increased sweet taste perception was significantly associated with increased satiety (adjusted odds ratios [ AOR] = 2.02; 95% CI : 1.15–4.57), decreased appetite ( AOR = 1.67; 95% CI : 1.04–3.25) and decreased craving ( AOR = 1.85; 95% CI : 1.05–3.29). Increased salty taste perception was associated with increased satiety ( AOR = 2.17; 95% CI : 1.16–5.17; all p < 0.05).

Conclusions

Self‐reported changes in taste perception during GLP‐1 or dual GIP/GLP‐1 RAS therapy were associated with favourable appetite‐related outcomes, suggesting a potential mechanism contributing to treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityIncretinsTaste PerceptionOverweightAppetite RegulationHumansFemaleCross-Sectional StudiesMaleMiddle AgedAdultGlucagon-Like Peptide-1 Receptor AgonistsGastric Inhibitory PolypeptideBody Mass Index

Stichwörter der Autor:innen

appetite regulationincretin‐based therapyobesity treatmentobservational studyweight management

Substanzen

IncretinsGlucagon-Like Peptide-1 Receptor AgonistsGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Center for Public Health, Department of Social and Preventive Medicine, Medical University of Vienna, Vienna, Austria.
  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Division of Exercise Physiology and Metabolism, Department of Sport Science, University of Bayreuth, Bayreuth, Germany.
  • Center for Public Health, Department of Epidemiology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Ali Kapan, Othmar Moser, Richard Felsinger, Thomas Waldhoer, Sandra Haider

Zitieren

APA

Kapan, A., Moser, O., Felsinger, R., Waldhoer, T., & Haider, S. (2025). Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study. Diabetes, Obesity and Metabolism, 27(9), 5008-5018. https://doi.org/10.1111/dom.16548

Vancouver

Kapan A, Moser O, Felsinger R, Waldhoer T, Haider S. Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study. Diabetes, Obesity and Metabolism. 2025;27(9):5008-5018. doi:10.1111/dom.16548

BibTeX
@article{Kapan2025,
  author = {Kapan, Ali and Moser, Othmar and Felsinger, Richard and Waldhoer, Thomas and Haider, Sandra},
  title = {Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {9},
  pages = {5008--5018},
  doi = {10.1111/dom.16548}
}
Kostenlos starten →